Evaxion Biotech A/S Overview
Valuation check: EVAX's PEG ratio is -1.55, below the Healthcare sector average of 1.26.
Get informed when a big investor buys or sells
+ Follow-1.55
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for EVAX is -1.55. That is below the Healthcare sector average of 1.26. Investors often review this figure alongside Evaxion Biotech A/S's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, EVAX currently prints -1.55 for PEG ratio, while the sector average sits near 1.26. That is roughly 223.5% below the sector mean. Large gaps often invite a closer look at Evaxion Biotech A/S's growth, margins, and balance sheet.
A PEG ratio of -1.55 for Evaxion Biotech A/S is not 'good' or 'bad' on its own. Compare it with the peer average (1.26) and with EVAX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting EVAX's PEG ratio (-1.55), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Evaxion Biotech A/S's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
